The company will not receive any of the proceeds from the sale of the securities by the selling stockholder.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LENZ:
- LENZ Therapeutics to Participate in Upcoming Investor Conferences
- Lenz Therapeutics reports Q2 EPS (40c), consensus (48c)
- LENZ Therapeutics Reports Second Quarter 2024 Financial Results
- Lenz Therapeutics submitted NDA for LNZ1000
- LENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of Presbyopia